Oncology News & Articles

1 Genetic polymorphisms in the matrix metalloproteinases, tissue inhibitors of metalloproteinases and bladder cancer susceptibility BJU International, June 10, 2013

2 A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACAG) in patients with locally advanced carcinoma of the bladder Urology, June 10, 2013    Clinical Article

3 Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis Cancer Epidemiology, June 10, 2013

4 Arylamine Adducts and Bladder Cancer in Lifelong Nonsmokers Cancer Epidemiology, Biomarkers & Prevention, June 10, 2013    Clinical Article

5 A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder Cancer Chemotherapy and Pharmacology, June 10, 2013    Clinical Article

6 Dietary consumption and diet diversity and risk of developing bladder cancer: results from the South and East China case-control study Cancer Causes and Control, June 10, 2013    Clinical Article

7 Characterization and outcomes of small cell carcinoma of the bladder using the Surveillance, Epidemiology, and End Results database American Journal of Clinical Oncology, June 10, 2013    Clinical Article

8 Associations of tea and coffee consumption with prostate cancer risk Cancer Causes and Control, June 10, 2013    Clinical Article

9 Egg consumption and risk of bladder cancer: a meta-analysis Nutrition and Cancer, May 24, 2013    Clinical Article

10 Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma The Journal of Urology, May 24, 2013    Clinical Article

11 The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence? World Journal of Urology, May 24, 2013    Review Article

12 Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base Full Text European Urology, May 24, 2013    Clinical Article

13 Selective transurethral resection of the prostate combined with transurethral incision of the bladder neck for bladder outlet obstruction in patients with small volume benign prostate hyperplasia (BPH): a prospective randomized study PLOS ONE, May 24, 2013    Clinical Article

14 Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer British Journal of Cancer, May 24, 2013

15 The natural history of secondary muscle-invasive bladder cancer Full Text BMC Urology, May 24, 2013    Clinical Article

16 Fibroblast Growth Factor Receptor 3 is a Rational Therapeutic Target in Bladder Cancer Molecular Cancer Therapeutics, May 24, 2013    Clinical Article

17 Interferon α in the treatment paradigm for non–muscle-invasive bladder cancer Urologic Oncology: Seminars and Original Investigations, May 24, 2013    Clinical Article

18 Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical bacillus calmette-guerin treatment The Journal of Urology, May 24, 2013    Clinical Article

19 Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk British Journal of Cancer, May 7, 2013    Clinical Article

20 Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer The Journal of Urology, May 7, 2013    Clinical Article

21 Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients Clinical and Translational Oncology, May 7, 2013    Clinical Article

22 Childbearing and the risk of bladder cancer: a nationwide population-based cohort study Full Text European Urology, May 7, 2013    Clinical Article

23 Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy International Journal of Cancer, May 7, 2013

24 Elevated 4-aminobiphenyl and 2, 6-dimethylaniline hemoglobin adducts and increased risk of bladder cancer among lifelong nonsmokers - The Shanghai Bladder Cancer Study Cancer Epidemiology, Biomarkers & Prevention, May 7, 2013

25 Impact of smoking and smoking cessation on oncologic outcomes in primary non–muscle-invasive bladder cancer Full Text European Urology, April 20, 2013    Clinical Article

1 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013

2 Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer: a randomized biomarker pilot study Clinical Cancer Research, May 6, 2013

3 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer Journal of the National Cancer Institute, May 1, 2013

4 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013

5 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013

6 Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial The Lancet Oncology, May 17, 2013

7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013

8 Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiology, April 22, 2013    Review Article

9 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013

10 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013

11 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 12, 2013

12 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013

13 Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study The Lancet Oncology, May 3, 2013

14 AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Journal of Clinical Oncology, April 15, 2013

15 Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Childrens Research Hospital experience Cancer, May 2, 2013

16 Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial analysis Journal of Clinical Oncology, April 30, 2013

17 Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer British Journal of Cancer, May 7, 2013

18 Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Journal of the National Cancer Institute, April 19, 2013    Evidence Based Medicine

19 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013

20 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, April 23, 2013